JP2017514856A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514856A5
JP2017514856A5 JP2016566651A JP2016566651A JP2017514856A5 JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5 JP 2016566651 A JP2016566651 A JP 2016566651A JP 2016566651 A JP2016566651 A JP 2016566651A JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
alkoxy
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514856A (ja
JP6483156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029409 external-priority patent/WO2015171722A1/en
Publication of JP2017514856A publication Critical patent/JP2017514856A/ja
Publication of JP2017514856A5 publication Critical patent/JP2017514856A5/ja
Application granted granted Critical
Publication of JP6483156B2 publication Critical patent/JP6483156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566651A 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ Active JP6483156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
US61/989,651 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (3)

Publication Number Publication Date
JP2017514856A JP2017514856A (ja) 2017-06-08
JP2017514856A5 true JP2017514856A5 (enExample) 2018-04-19
JP6483156B2 JP6483156B2 (ja) 2019-03-13

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566651A Active JP6483156B2 (ja) 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ

Country Status (33)

Country Link
US (4) US9873679B2 (enExample)
EP (1) EP3140296B1 (enExample)
JP (1) JP6483156B2 (enExample)
KR (1) KR102336370B1 (enExample)
CN (1) CN106458976B (enExample)
AR (1) AR100328A1 (enExample)
AU (1) AU2015256120B2 (enExample)
BR (1) BR112016024936A2 (enExample)
CA (1) CA2948161C (enExample)
CL (1) CL2016002809A1 (enExample)
CY (1) CY1120340T1 (enExample)
DK (1) DK3140296T3 (enExample)
EA (1) EA033250B1 (enExample)
ES (1) ES2674531T3 (enExample)
HR (1) HRP20180641T1 (enExample)
HU (1) HUE039288T2 (enExample)
IL (1) IL248668B (enExample)
MA (1) MA39427B1 (enExample)
MX (1) MX378160B (enExample)
MY (1) MY181959A (enExample)
NZ (1) NZ727146A (enExample)
PE (1) PE20161363A1 (enExample)
PH (1) PH12016502034B1 (enExample)
PL (1) PL3140296T3 (enExample)
PT (1) PT3140296T (enExample)
RS (1) RS57170B1 (enExample)
SG (1) SG11201609170UA (enExample)
SI (1) SI3140296T1 (enExample)
SM (1) SMT201800342T1 (enExample)
TN (1) TN2016000444A1 (enExample)
TR (1) TR201809633T4 (enExample)
TW (1) TWI659951B (enExample)
WO (1) WO2015171722A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2671402T3 (es) * 2014-05-07 2018-06-06 Bristol-Myers Squibb Company Moduladores de pirrolidina GPR40 para el tratamiento de enfermedades tales como diabetes
WO2015171722A1 (en) * 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
US10865201B2 (en) 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2018049324A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
MX2021000100A (es) 2018-07-13 2021-03-25 Gilead Sciences Inc Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1).
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2023014197A (es) 2021-06-16 2024-01-18 Celgene Corp Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
BR112012007979A2 (pt) * 2009-10-06 2016-03-29 Bristol Myers Squibb Co moduladores de gpr40 de pirrolidina
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
EA201590951A1 (ru) 2012-11-16 2015-08-31 Бристол-Майерс Сквибб Компани Дигидропиразольные модуляторы gpr40
SG11201503559TA (en) * 2012-11-16 2015-06-29 Bristol Myers Squibb Co Pyrrolidine gpr40 modulators
CA2891535A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
PL2920165T3 (pl) 2012-11-16 2017-04-28 Bristol-Myers Squibb Company Dihydropirazolowe modulatory gpr40
WO2015169728A1 (en) 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
EP3140294A1 (en) 2014-05-07 2017-03-15 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
WO2015171722A1 (en) * 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Similar Documents

Publication Publication Date Title
JP2017514856A5 (enExample)
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP6130964B2 (ja) Apj受容体のトリアゾールアゴニスト
JP7611278B2 (ja) 金属酵素阻害剤化合物
JP2018505203A5 (enExample)
JP2017508794A5 (enExample)
JP2016516043A5 (enExample)
JP5487202B2 (ja) 新規甲状腺ホルモンβ受容体作動薬
JP2024514010A (ja) カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP2016520128A5 (enExample)
JP2015500887A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2017508795A5 (enExample)
JP2017529389A5 (enExample)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2016526576A5 (enExample)
CA2903288A1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2016525136A5 (enExample)
JP2013518110A (ja) 疼痛および他の適応症の治療用の医薬組成物
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2016513696A5 (enExample)
JP2021512114A5 (enExample)
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
JP2016513681A5 (enExample)
JP2013523814A5 (enExample)